Literature DB >> 33309583

Ainsliaea fragrans champ. Extract prevents cervicitis in BALB/c mice and regulates MyD88-NF-κB signaling pathway in MALP-2-stimulated RAW264.7 cells.

Xiaobing Lin1, Xiaofei An2, Lingling Wang3, Junhan Zhang4, Abudusaimi Abuduwaili5, Hao Wang6, Ming Yan7.   

Abstract

Ethnopharmacological relevance Ainsliaea fragrans Champ. (A. fragrans) is used to treat infection of the lower genital tract in gynecology, such as cervicitis and pelvic inflammatory disease. This study analyzed the therapeutic efficiency of A. fragrans on cervicitis and the inhibition mechanism of AF-p2 in MALP-2-stimulated RAW264.7 cells. Materials and methods The anti- Ureaplasma urealyticum (Uu) activity of A. fragrans and AF-p2 were determined by antimicrobial susceptibility testing. The activity of A. fragrans extracts (AFext) was evaluated in female BALB/c mice with cervicitis induced by Uu. Furthermore, the therapeutic mechanism of AFext and AF-p2 on myeloid differentiation factor 88 (MyD88) pathway were studied in macrophage activating lipopeptide-2 (MALP-2) irritated RAW264.7 cells. Results AFext could suppress the proliferation of Uu in vitro, including the azithromycin resistant strains. Meanwhile, AFext prevented cervicitis caused by Uu infection in BALB/c mice. Moreover, both AFext and AF-p2 could significantly suppress the nitric oxide (NO) production as well as other proinflammatory cytokines (IL-1β,IL-6,TNF-α) in MALP-2 stimulated RAW264.7 cells. Moreover, AF-p2 also down-regulated iNOS, p65, Iκ-Bα, MyD88 and cyclooxygenase-2 (COX-2) levels in RAW264.7 cells. Conclusion This study indicated that AFext had a therapeutic effect in cervicitis induced by Uu infection. Furthermore, the lead compound AF-p2 showed an anti-infectious effect in MALP-2 irritated RAW264.7 cells through downregulating MyD88-NF-κB signaling pathway.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ainsliaea fragrans Champ.; Cervicitis; Mycoplasma; NF-κB

Year:  2020        PMID: 33309583     DOI: 10.1016/j.jep.2020.113684

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  2 in total

1.  Integrated Metabolomics and Network Pharmacology Study on the Mechanism of Kangfuxiaoyan Suppository for Treating Chronic Pelvic Inflammatory Disease.

Authors:  Zhengyi Zhang; Ziye Xie; Shujing Lv; Yulian Shi; Chuanjia Zhai; Xuejiao Li; Bin Qiao; Xiaoyan Gao
Journal:  Front Pharmacol       Date:  2022-02-04       Impact factor: 5.810

2.  To explore the therapeutic effect of Kangfuxiaomi shuan II on cervicitis in rats.

Authors:  Xiao-Mei Duan; Yu-Sheng Xu; Xiu-Qin Li; Xiu-Ying Ma; Jian-Ting Zhao; Gui-Ke Li; Heng Liu
Journal:  Acta Cir Bras       Date:  2021-11-29       Impact factor: 1.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.